Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 25, 2017. The report serves as a transaction notification regarding a specific equity event involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure limited to a specific share transaction.
| Metric | Value |
|---|---|
| Instrument Type | American Depositary Shares (ADSs) |
| Transaction Volume | 10,251 ADSs |
| Transaction Price | $38.72 per ADS |
| Tax Withholding | 3,926 ADSs |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction: the vesting of an award over 10,251 ADSs granted to Mr. B McNamara (CEO, Consumer Healthcare) under the GlaxoSmithKline Share Value Plan. This award was granted to compensate for the value of awards forfeited upon leaving Novartis, adjusted for time pro-rating.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a mandatory disclosure of a share vesting event and the automatic withholding of shares to meet tax liabilities.
Investor Verification Points
- Verify the identity of the executive involved: Mr. B McNamara, CEO of Consumer Healthcare.
- Confirm the nature of the transaction: Vesting of a compensatory award related to prior Novartis employment.
- Note the net share impact: 10,251 ADSs vested, with 3,926 withheld for taxes, resulting in a net increase of 6,325 ADSs for the executive.
- Confirm the transaction date: January 23, 2017.